Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.
about
CNS active O-linked glycopeptidesModulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist.Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligandsPharmacological traits of delta opioid receptors: pitfalls or opportunities?Molecular Pharmacology of δ-Opioid Receptors.The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice.Development of a bioavailable μ opioid receptor (MOPr) agonist, δ opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance.Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analoguesModulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.Variation of the net charge, lipophilicity, and side chain flexibility in Dmt(1)-DALDA: Effect on Opioid Activity and Biodistribution.Rapid Synthesis of Boc-2',6'-dimethyl-l-tyrosine and Derivatives and Incorporation into Opioid Peptidomimetics.In Vivo Effects of μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Peptidomimetics Following Acute and Repeated Administration.
P2860
Q27021529-106BE319-A032-4719-B4FE-AEB2D6F65820Q36382976-5053D36D-E917-4F05-ADBF-C21758750E2CQ36635468-E4368415-0875-441A-98AB-B5FD610E60AAQ36745738-EBFC5C4B-FD96-494A-AA81-E2BB883472B4Q36920342-DB540F86-4E20-4580-818A-7652AD340239Q37062556-51FC2317-7616-4C30-8F22-2FACBF59D1B4Q37347930-2F636E99-6912-4BB8-BE4C-AAF341EE1A57Q37714225-D1DCF5DD-8B13-4442-AACD-0EC2978BD63FQ39033568-075316D3-FF6E-4AA2-A0EF-5897BDFC3A71Q39299621-7016DB54-D612-4223-A946-E4D3278012B0Q40980675-2625B8B1-47C5-43B6-B017-1B9D80EA4652Q41768815-566AF40D-4069-4EDF-92D9-E341FEBBFC84Q42412184-3451DF4E-935B-4321-8AA4-A17C783D0A2FQ43132505-AFB5E737-74A8-4DBA-B7D4-20ACA7AD53E1Q47708906-D1AFFF40-39C7-470E-8912-2154C3BA9D2A
P2860
Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Development and in vitro chara ...... ntagonist opioid tetrapeptide.
@ast
Development and in vitro chara ...... ntagonist opioid tetrapeptide.
@en
type
label
Development and in vitro chara ...... ntagonist opioid tetrapeptide.
@ast
Development and in vitro chara ...... ntagonist opioid tetrapeptide.
@en
prefLabel
Development and in vitro chara ...... ntagonist opioid tetrapeptide.
@ast
Development and in vitro chara ...... ntagonist opioid tetrapeptide.
@en
P2093
P2860
P356
P1433
P1476
Development and in vitro chara ...... ntagonist opioid tetrapeptide.
@en
P2093
Henry I Mosberg
Irina D Pogozheva
John R Traynor
Katarzyna Sobczyk-Kojiro
Lauren C Purington
P2860
P304
P356
10.1021/CB200263Q
P577
2011-10-11T00:00:00Z